Can Visceral Fat Be Surgically Removed?

Visceral fat, the deep abdominal fat surrounding your internal organs, is strongly linked to serious health conditions including type 2 diabetes, cardiovascular disease and fatty liver disease. Many people wonder whether it can be surgically removed, particularly given the popularity of procedures such as liposuction. The short answer is no: surgery cannot directly remove visceral fat. Understanding why, and what evidence-based treatments do work, is essential for anyone looking to reduce their metabolic risk. This article explains the science, outlines NHS-recommended approaches and clarifies when to seek medical advice.

What exactly is visceral fat and why does it matter for your health?

Visceral fat is metabolically active fat stored deep in the abdominal cavity that releases inflammatory chemicals directly into the portal circulation, raising the risk of type 2 diabetes, cardiovascular disease and fatty liver disease.

Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it poses significantly greater health risks than subcutaneous fat (the fat you can pinch beneath the skin). Unlike subcutaneous fat, visceral fat releases inflammatory chemicals and free fatty acids directly into the portal circulation, which supplies the liver.^[1][2] This biological activity links excess visceral fat to a cluster of serious conditions.

Elevated visceral fat is associated with an increased risk of:

• Type 2 diabetes, through impaired insulin sensitivity

• Cardiovascular disease, including raised blood pressure and unfavourable cholesterol profiles

• Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD)

• Certain cancers, including colorectal and breast cancer

• Obstructive sleep apnoea

Visceral fat cannot be seen or felt from the outside, which makes it particularly deceptive. A person with a relatively normal body weight can still carry a clinically significant amount of visceral fat, a pattern sometimes described as being "metabolically obese, normal weight". Waist circumference is a practical proxy measure used in clinical settings: NHS guidance identifies a waist measurement above 88 cm in women and above 102 cm in men as indicating substantially increased metabolic risk. NICE also recommends using waist-to-height ratio as a complementary measure; a ratio of 0.5 or above is associated with increased health risk in most adults.

Understanding the distinction between visceral and subcutaneous fat is important because the two types respond differently to interventions. Visceral fat is generally more responsive to lifestyle change than subcutaneous fat, which has both clinical and practical implications for how it should be managed.

Can visceral fat actually be removed with surgery?

Visceral fat cannot be surgically removed; liposuction only targets subcutaneous fat and clinical evidence confirms it produces no meaningful reduction in visceral fat or associated metabolic risk factors.

Visceral fat cannot be safely or effectively removed by surgical procedures such as liposuction, and no surgical technique currently exists that targets visceral fat directly. Liposuction removes subcutaneous fat, the layer sitting just beneath the skin, and does not reach the deep intra-abdominal deposits that constitute visceral fat. Clinical research, including a study published in the New England Journal of Medicine (Klein et al., 2004), confirmed that large-volume liposuction produces no meaningful reduction in visceral fat mass or in the metabolic risk factors associated with it, such as insulin resistance, blood pressure or lipid levels.

Bariatric surgery, such as Roux-en-Y gastric bypass or sleeve gastrectomy, does lead to substantial reductions in visceral fat, but this is an indirect effect. The surgery works by restricting caloric intake, altering gut hormone signalling and, in bypass procedures, changing nutrient absorption. The resulting sustained calorie deficit and hormonal changes cause the body to preferentially mobilise visceral fat stores. Bariatric surgery is therefore not a procedure designed to remove visceral fat; rather, visceral fat reduction is one of several metabolic benefits that follow significant weight loss.

It is also worth noting that omentectomy (surgical removal of the omentum, a fatty tissue layer in the abdomen) has been studied in small trials as a targeted approach. However, evidence to date does not support omentectomy as a standalone intervention for metabolic improvement, and it is not recommended in UK clinical practice outside of research settings.

In summary, surgery cannot remove visceral fat in the way it removes subcutaneous fat. Any surgical pathway that leads to visceral fat reduction does so through the downstream effects of sustained weight loss, not through direct excision.

What treatments do NHS doctors recommend for visceral fat?

NHS doctors recommend structured weight management programmes, dietary change and physical activity as first-line treatment, escalating to licensed medicines or bariatric surgery based on BMI and comorbidities.

NHS doctors recommend a structured combination of dietary change, increased physical activity and, where appropriate, pharmacological or surgical intervention as the evidence-based approach to reducing visceral fat. There is no single treatment; management is individualised based on a person's overall cardiovascular risk, BMI, comorbidities and readiness to change.

For most people, the first-line approach involves referral to a structured weight management programme. NHS Tier 2 and Tier 3 services offer behavioural support, dietary counselling and physical activity guidance. NICE recommends these pathways before escalating to pharmacological treatment.

Where lifestyle intervention alone is insufficient, licensed weight management medicines may be considered. Eligibility criteria differ by medicine and are set out in individual NICE Technology Appraisals; they typically require a minimum BMI threshold, the presence of at least one weight-related comorbidity, and in many cases access through a specialist weight management service. Ethnicity-adjusted BMI thresholds (generally 2.5 kg/m² lower) apply for people from South Asian, Chinese, Black African or African-Caribbean backgrounds. Orlistat has lower BMI thresholds than the injectable agents and may be initiated in primary care. Currently licensed options in the UK include:

• Orlistat, which reduces dietary fat absorption (available in primary care at lower BMI thresholds; see NICE CKS for current criteria)

• Semaglutide (Wegovy), a GLP-1 receptor agonist available as a weekly injection (doses up to 2.4 mg, with a 7.2 mg strength also MHRA-authorised) and as an oral tablet (Wegovy 25 mg tablets, MHRA-authorised June 2026); eligibility is defined in the relevant NICE Technology Appraisal

• Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist, MHRA-authorised for chronic weight management; eligibility is defined in the relevant NICE Technology Appraisal^[15][16]

• Orforglipron (Foundayo), an oral GLP-1 receptor agonist, licensed in the UK for chronic weight management; prescribing criteria should be confirmed against the current NICE Technology Appraisal and MHRA-authorised SmPC^[17]

Bariatric surgery is considered for people with a BMI of 40 kg/m² or above, or 35 kg/m² or above with significant comorbidities, when other interventions have not achieved adequate weight loss.^[12] NICE also recommends considering metabolic surgery at lower BMI thresholds for people with recent-onset type 2 diabetes, with ethnicity adjustments applied in the same way as for medicines.^[18] Integrated Care Boards (ICBs) make local commissioning decisions about which services and medicines are funded in their area, so availability may vary across England.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be considered.

Are there non-surgical ways to reduce visceral fat that really work?

Yes, sustained calorie deficit combined with regular aerobic exercise is the most effective approach, with pharmacological treatments such as GLP-1 receptor agonists providing additional benefit where clinically indicated.

Yes, non-surgical approaches are the most effective and evidence-supported methods for reducing visceral fat, and they consistently outperform surgical fat removal in terms of metabolic benefit. Visceral fat is particularly responsive to a sustained calorie deficit combined with regular aerobic exercise, making lifestyle modification the cornerstone of management.

Diet plays a central role. Reducing overall caloric intake, limiting ultra-processed foods, refined carbohydrates and added sugars, and following a Mediterranean-style or low-glycaemic dietary pattern have all been associated with preferential reductions in visceral fat in clinical studies and systematic reviews. Alcohol reduction is also relevant, as alcohol is independently associated with visceral fat accumulation.

Physical activity is highly effective. Both aerobic exercise (such as brisk walking, cycling or swimming) and resistance training contribute to visceral fat loss, though aerobic exercise appears to have a particularly strong effect. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults.^[19][20]

Sleep and stress management are increasingly recognised as important. Chronic sleep deprivation and elevated cortisol levels (associated with prolonged psychological stress) promote visceral fat deposition through hormonal pathways involving cortisol and insulin.^[25] Addressing these factors supports overall metabolic health.

Pharmacological treatment, where clinically indicated, can substantially augment lifestyle efforts. GLP-1 and dual GIP/GLP-1 receptor agonists have demonstrated meaningful reductions in visceral fat in clinical trials, as measured by imaging studies; these reductions appear to be driven primarily by overall weight loss and the associated calorie deficit, with some evidence of additional metabolic effects that requires further research to fully characterise.^[26] These medicines are prescribed, not available over the counter, and require clinical assessment to determine suitability.

The evidence is clear that consistent, sustained lifestyle change produces durable reductions in visceral fat and the associated health risks.

When should you speak to a GP about visceral fat levels?

Speak to a GP if your waist circumference exceeds 88 cm (women) or 102 cm (men), your waist-to-height ratio is 0.5 or above, or you have weight-related conditions such as type 2 diabetes or high blood pressure.

You should speak to a GP about visceral fat if your waist circumference exceeds the thresholds associated with increased metabolic risk (88 cm or above for women, 102 cm or above for men), or if your waist-to-height ratio is 0.5 or above, or if you have been told you have a raised BMI alongside conditions such as type 2 diabetes, high blood pressure, raised cholesterol or fatty liver disease. These combinations suggest that visceral fat may be contributing to your overall health risk and that a structured management plan would be beneficial.

A GP can arrange relevant investigations, which may include:

• Fasting blood glucose and HbA1c to assess diabetes risk

• Fasting lipid profile to evaluate cardiovascular risk

• Liver function tests if metabolic liver disease is suspected

• Blood pressure measurement

You should also speak to your GP if you have tried lifestyle changes for several months without meaningful progress, as this may indicate that additional support, such as referral to a structured weight management service or consideration of pharmacological treatment, is appropriate.

Contact NHS 111 if you develop symptoms that may suggest a complication, such as sudden severe abdominal pain, which warrants prompt assessment. Call 999 if you experience symptoms of a heart attack or stroke: for a heart attack, these include chest pain that may spread to the arm or jaw, shortness of breath and sweating; for a stroke, use the FAST test (Face drooping, Arm weakness, Speech difficulty, Time to call 999).

Suspected side effects from any prescribed medicine should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Proactively discussing visceral fat with your GP is a positive step: early intervention consistently produces better long-term outcomes than waiting until complications develop.

Scientific References

1. Visceral fat and metabolic inflammation: the portal theory revisited (Item F et al.).
2. Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in vitro.
3. Calculate your waist to height ratio.
4. Adults with a large waist are 5 times more likely to get type 2 diabetes.
5. Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity.
6. Absence of an Effect of Liposuction on Insulin Action and Risk Factors for Coronary Heart Disease (Klein S et al.).
7. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease (Klein S et al.) — PubMed record.
8. The effect of omentectomy added to bariatric surgery on metabolic outcomes (Lee Y et al.).
9. Omentectomy in Addition to Bariatric Surgery — a 5-Year Follow-up. Obesity Surgery..
10. Omentectomy in addition to gastric bypass surgery and influence on insulin sensitivity: a randomized double blind controlled trial. Clinical Nutrition..
11. A prospective randomized study comparing patients with morbid obesity submitted to sleeve gastrectomy with or without omentectomy. Obesity Surgery..
12. Overweight and obesity management (NG246): Medicines and surgery.
13. Overweight and obesity management (NG246) Appendix A1: Summary of evidence from surveillance — ethnicity-adjusted BMI thresholds.
14. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity.
15. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
16. Tirzepatide — BNF NICE.
17. UK first in Europe to authorise orforglipron (Foundayo) for weight management and type 2 diabetes.
18. NICE TA1152 draft scope post-referral — bariatric surgery at lower BMI thresholds for recent-onset type 2 diabetes.
19. UK Chief Medical Officers' Physical Activity Guidelines.
20. Physical activity guidelines for adults aged 19 to 64.
21. Aerobic Exercise and Weight Loss in Adults: A Systematic Review (Jayedi A et al.).
22. Impact of Different Exercise Modalities on Visceral Adipose Tissue in Normal Weight and Low-Overweight Individuals: A Systematic Review and Meta-Analysis. Biological Research for Nursing..
23. Effects of concurrent training on fat mass and its distribution in individuals with overweight or obesity. BMC Public Health..
24. Comparative Efficacy of Exercise Type on Visceral Adipose Tissue in Patients With Prediabetes and Type 2 Diabetes Mellitus. Obesity Reviews..
25. Sleep loss as a cardiometabolic risk factor: a narrative review. Journal of Clinical Sleep Medicine..
26. Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.).

Frequently Asked Questions